0.00Open0.00Pre Close0 Volume0 Open Interest15.00Strike Price0.00Turnover123.83%IV-38.89%PremiumDec 20, 2024Expiry Date4.20Intrinsic Value100Multiplier28DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type-0.7849Delta0.0807Gamma2.37Leverage Ratio-0.0182Theta-0.0077Rho-1.86Eff Leverage0.0087Vega
Kura Oncology Stock Discussion
Kura Oncology Announces Publication of Ziftomenib Phase 1 Results in The Lancet Oncology | KURA Stock News
$Kura Oncology (KURA.US)$
No comment yet